US › Healthcare

Standard Biotools Inc (LAB)

US · Healthcare · Medical Devices

$0.63-4.55%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$20.1M

Revenue YoY

-7.6%

Net profit

$-26.8M

EPS

$-0.05

EPS estimate

$-0.03

Net margin

-133.1%

EPS came in at -0.05 against a street estimate of -0.03 — a miss of 66.7%.

Key statistics

Market cap

$260.3M

Forward P/E

0.0

P/B

0.52

Book value

$1.38

EPS (TTM)

$-0.13

52-week high

$1.72

52-week low

$0.63

50-day MA

$0.71

200-day MA

$0.97

Beta

1.35

Analyst view

Analysts rate Standard Biotools Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $1.35.

Shareholding

Insiders

2.02%

Institutions

75.87%

Largest institutional holders

Fund	Stake
Casdin Capital, LLC	22.62%
Viking Global Investors LP	14.94%
Mak Capital One LLC	7.34%
Long Focus Capital Management, LLC	5.99%
Vanguard Capital Management, LLC	3.12%
BlackRock Inc	2.10%
Hollow Brook Wealth Management, LLC	1.40%
Neuberger Berman Group LLC	1.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Standard Biotools Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.